1.450USD+0.69%Mkt Cap: 61.24M $P/E: —1d ago
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobr…
Industry Peers
Medical DevicesIndicators:|
Key Statistics
Company
Market Cap61.24M $
Enterprise Value55.96M $
Revenue (TTM)88.55M $
Gross Profit67.14M $
Net Income (TTM)-54.00M $
Revenue/Share2.151 USD
Last Price1.450 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees296
CountryUS
SectorHealthcare
IndustryMedical Devices
ISINUS7458481014
Valuation
P/E (Trailing)—
P/E (Forward)-1.39
PEG—
EV/EBITDA-1.09
EV/Revenue0.63
P/S0.69
P/B1.34
EPS (TTM)-1.30
EPS (Forward)-1.04
52W Range
1.13012% of range3.880
52W High3.880 USD
52W Low1.130 USD
Profitability
Gross Margin74.19%
Oper. Margin-62.94%
EBITDA Margin-57.78%
Profit Margin-59.67%
ROE-99.79%
ROA-41.77%
Growth
Revenue Growth-8.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.38M $
CapEx (TTM)452.00K $
FCF Margin-9.44%
FCF Yield-13.65%
Net Debt-5.28M $
Net Debt/EBITDA0.10
Balance Sheet
Debt/Equity1.04
Current Ratio4.91
Quick Ratio3.85
Book Value/Sh1.083 USD
Cash/Share1.458 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.400 USD
Upside (mean)+134.5%
Target Range2.500 USD – 5.000 USD
$2.500+134.5% to mean$5.000
# Analysts5
Ownership
Shares Out.42.24M
Float36.97M
Insiders4.89%
Institutions78.83%
Short Interest
Short Ratio2.0d
Short % Float3.23%
Short % Out.2.72%
Shares Short1.15M
Short (prev mo.)2.82M
Technical
SMA 501.412 (+2.7%)
SMA 2001.631 (-11.1%)
Beta0.31
S&P 52W Chg20.25%
Avg Vol (30d)441.61K
Avg Vol (10d)229.66K
Technical Indicators
RSI (14)52.1
MACD0.0202
MACD Signal0.0093
MACD Hist.+0.0110
BB Upper1.587 USD
BB Middle1.378 USD
BB Lower1.169 USD
BB Width30.37%
ATR (14)0.1188 USD
Vol Ratio (20d)0.33x